ImpriMed: Funding, Investors & Team (Sep 2026)
ImpriMed offers advanced personalized medicine that is conveniently available for pets suffering from blood cancer conditions. The company's main offering, the Personalized Prediction Profile, has been utilized by qualified veterinary oncologists, benefiting more than 4,000 dogs diagnosed with lymphoma and leukemia. With ImpriMed's assistance, veterinarians can promptly and confidently make treatment choices. This groundbreaking cancer care approach has been documented in a scientific journal and showcased at prominent conferences, garnering support from over 200 veterinary oncologists at over 80 specialty hospitals across the United States.
ImpriMed has raised $23.0M across 3 funding rounds on record, the most recent a Series A of $23.0M announced in Dec 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ImpriMed Company Profile and Key Stats
Latest funding round on record: Dec 2023.
ImpriMed Funding Rounds
2 of 3 rounds were announced without a disclosed amount and are excluded from the total.
ImpriMed announced a Seed in Aug 2022; the amount was not disclosed.
1.3 years later, an undisclosed round was announced in Nov 2023 with no disclosed amount.
1 month later, a Series A of $23.0M was announced in Dec 2023.
ImpriMed Founders and Leadership Team
Contact details for the ImpriMed team: 1 of 1 has an email address on file.
Start 14-day free trial →ImpriMed Funding Compared to Other Biotechnology Startups
ImpriMed's latest round of $23.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ImpriMed in Biotechnology and Palo Alto
Companies Similar to ImpriMed
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
ImpriMed Funding FAQs
What does ImpriMed do?
ImpriMed offers advanced personalized medicine that is conveniently available for pets suffering from blood cancer conditions. The company's main offering, the Personalized Prediction Profile, has been utilized by qualified veterinary oncologists, benefiting more than 4,000 dogs diagnosed with lymphoma and leukemia. With ImpriMed's assistance, veterinarians can promptly and confidently make treatment choices. This groundbreaking cancer care approach has been documented in a scientific journal and showcased at prominent conferences, garnering support from over 200 veterinary oncologists at over 80 specialty hospitals across the United States.
How much funding has ImpriMed raised?
ImpriMed has raised $23.0M across 3 rounds on record. The most recent is a Series A of $23.0M announced in Dec 2023.
When did ImpriMed last raise funding?
ImpriMed's most recent funding round on record is a Series A of $23.0M, announced in Dec 2023.
Who is the CEO of ImpriMed?
Sungwon Lim is listed as CEO at ImpriMed.
Where is ImpriMed headquartered?
ImpriMed is based in Palo Alto, California, United States.
How many employees does ImpriMed have?
ImpriMed is in the 11-50 employee band.
How does ImpriMed's funding compare to other Biotechnology startups?
ImpriMed's latest round of $23.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's ImpriMed Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ImpriMed is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.